Stifel Nicolaus Downgrades Pharmasset (VRUS) to Hold
Tweet Send to a Friend
Stifel Nicolaus downgrades Pharmasset, Inc. (Nasdaq: VRUS) from Buy to Hold and sets a fair value price target of $21 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


